Skip to main content
Delfa

← All assets

AVP-786

6 trials in this asset. Source: ClinicalTrials.gov, as of July 21, 2026.

Trials

6

Ongoing

0

Recruiting

0

Completed

3

Sites

730

Countries

28

Endpoints

128

Composite endpoints

0

Distinct sites and countries across this asset's trials. A site running several of its trials counts once, matching the map. All 128 linked ClinicalTrials.gov endpoints are classified into the categories below. Trial and endpoint linkage does not by itself establish treatment attribution for every endpoint.

Development

Where the program stands

Trials by phase

Phase 3
6

Trials by status

Completed
3
Terminated
3

Evidence coverage

What this asset has been measured on

Endpoints grouped into outcome categories, ranked by how often they are measured across this asset's trials.

Behavior / neuropsychiatric
64
Caregiver / quality of life
28
Safety / tolerability / PK
12
Other (unclassified)
12
Global cognition
8
Other clinical outcomes
4

Most-measured metrics

Top 20 metrics across this asset's endpoints

Normalized metric codes are available for 42 of 128 classified ClinicalTrials.gov endpoints for this asset; the ranking below covers that coded subset.

Neuropsychiatric Inventory (NPI)Behavior

34

ADAS-CogCognition

4

Mini-Mental State Examination (MMSE)Cognition

4

Trials

Trials for this asset

Every trial for this asset, with the same search, filters, and sort as the Trials tab.

6 of 6

Alzheimer’s disease and related dementias trials
Asset / Disease areaKey I/E criterionEvidence
NCT02446132Long Term, Extension Study of the Safety and Efficacy of AVP-786 for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type

AVP-786

Alzheimer’s disease

Alzheimer's diseasePh 3Terminated227Sep 2024-results
NCT03393520Assessment of the Efficacy, Safety, and Tolerability of AVP-786 (Deudextromethorphan Hydrobromide [d6-DM]/Quinidine Sulfate [Q]) for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type

AVP-786

Alzheimer’s disease

Alzheimer's diseasePh 3Completed211Nov 2023-
NCT02442765Efficacy, Safety and Tolerability of AVP-786 for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type

AVP-786

Alzheimer’s disease

Alzheimer's diseasePh 3Completed126Jan 2019-results
NCT04464564Study to Assess the Efficacy, Safety, and Tolerability of AVP-786 for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type

AVP-786

Alzheimer’s disease

Alzheimer's diseasePh 3Terminated106Jun 2024-results
NCT04408755Assessment of the Efficacy, Safety, and Tolerability of AVP-786 for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type

AVP-786

Alzheimer’s disease

Alzheimer's diseasePh 3Terminated95Jun 2024-results
NCT02442778Efficacy, Safety, and Tolerability of AVP-786 for the Treatment of Agitation in Participants With Dementia of the Alzheimer's Type

AVP-786

Alzheimer’s disease

Alzheimer's diseasePh 3Completed83Aug 2019-results

Showing 1-6 of 6 trials